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11 o e:1oYi Thmml~Wtolxmie n• La~e, tnterniltiomll Trkd 
" " of the OP IIb/ll~ Ifthibltor F.~tiflbetlde in I~tkmts 
With A©uto Corene~ry Syndromes 
M, McCIur~, N,~, Kl~im~n, LG, I~i~rd~n, R Spar'dtpani, E,J, T_~9!, R, D_i~,~. 
RM, Ca!lff, ID. GrCU@r, KR  Kar~h, RA, H aeTit~Jt0~, FOr ~ PUR-~U!T 
tnve, f~ti~to.'~; 13~k~ Clm¢#l Re,:~a¢h Institute, C~rham, NC, USA 
~;k~Otmd: Ptatalgt (pll) inl~ibition vi~ GP IIl~ll!a r~Pt0r b l0¢k~ =S as. 
sociatecJ with ~ low I~jt pot~nti=ally ~npa~z]nt lnctd~nce of thr0mbocytopon=a 
(T)~ We sought to exel~tine th~ i ~  O! T in PURSUIT, a mutticenter 
intem~ lionel cliniC.~l thpl 5tuclying this rn~de of ptatelet inhlb~tl0n. 
Methe.~: 10,948 p a.tients with a~ non.ST elcveltion acule c=anap/syn. 
dr0me for <24 ho_g~ va~e ~ e c l  to treatment with eptifdpatide, a
platalet GP Itb/llla receptor antagortist, or ~bo  for up to 96 hours. Pa- 
tients received asl~rin and hepmin. T was defim~l as acute (pit <50% Of 
baseline or <100,000/ram3), se~mm (pit <50,Q00 mrr,3), or profound (pit 
< 20,QO0~mm :~). 
Results: 
O~e rail (n = 10.IB49) Eptdzbahde tn = 4.679) PreceDe (n - 4.696) 
ACUte T 6 9% 6 B% 6 7% 
Sea, ere T 05% 06% 04% 
Profound e 1% 02% 0 6% 
Concluszon: T Occurs infrequently but not rarely arp~ng patients v,~th 
non-ST elevation acute COronary syndromes. The overaJl in.dance of T 
was similar between treatment groups, with a slight excess of severe and 
profound T associated with eptifil~tide. The clinical signififance of T in this 
pOpular=on remoras to be deterr~ned. 
1028-108]  Prior Aspirin use Potentiates the of Efhmt GP 
IIbJIIla Inhibition in Patients With Non-ST 
Elevation Acute Coronary Syndromes 
JH. Alexander, R.A. Hardngton, A. Guerci, B.D. Weathedey. K.R Karsch. 
R,M. Califf, E.J, Topoi, A.M. Linceff, P.W. Armstrong. F~rthe PURSUIT 
Investigators: Duke Cl:ncal Research Insbtute. Durham. NC, USA 
BaCkgrOund: ASpirin (ASA) is the moss commonly used anti-platetet agent in 
pts with coronary artery disease. The additional benefit of GP lib/Ills inhibition 
during an acute coronary event in pts already on ASA iS unknown. 
MethOds: The PURSUIT tnal randomized 10,948 pts with non-ST eleva- 
tion acute coronary syndromes to bolus and infusion of eptitibatide or placabc 
for up to 72 hours. Pts were followed for 3Od death or non-fatal MI. Protocol 
ASA use (160 mg then 75.-~325 rapid) was recommended in all Lots, We stud- 
ied the relationship between poor ASA use (within 2 weeks) and treatment 
effect of eptitibalide. 
Results: Overall, prior ASA use was 63.6% and did not vary across 
treatment arms. Death or MI by ASA use and treatment is diSplayed: 
Placebo Epfdibatide RR 95% CI 
No prior aspirin 12 9% 13 1% 102 (0.84, 1.25) 
Prior aspinn" 173% 149% 084 (0.73, 0.96) 
Conclusions: Pts with prior ASA use derived particular benefit from GP 
lib/Ilia inhibition. While this counters the expectation that them would be 
less potential therapeutic effect in patients with prior antiplatelet use, the 
mechanism of ASA resistance may be explanatory and deserves further 
study. 
. . . . . . . . . .  Plotolot AggmgMIon RHponss Of EptlfllN#lde 
.A.d~inl.MeyOdlntmvonouMy in Poti~lto With 
unstable Angina or Non-Q;Waw ~ L M  
InfnP~'~en 
L J¢nnin~,, E, Tardiff, O, Phillips, R, Scarborough, M, Kilt, O, Gral~f, 
Unlv~r~ty at7~, M~;mp~. 'rN; ~e  UnivaC, {~a,~n, NC: COR 
B~(~-(,Jr..e; Eptifit~ttd0 i~ ~ pint,let tit~nne~n tm:.eplor emt~l~t  eu~tat~ 
for IV edmin~tratior), PERIGEE is ~ ~ul~igo'y 0f PURSUIT, # m~ltic~ntar, 
r~n~mized placer]o-controlled tr~l in p~tienta with unsWplo l~ngin,~ or SuS, 
p~t~t MI without ST 5egm0nl L~ov~tiori, 
M~tho~; A pll~c,~t~o group an~ e tr~tm~nt regimen at a 180 ~g)kg 10ol~s 
follOWed by el 2,0 Hg/kgJmin infus0on rate Up to 7~ hr were inve~gat_ed, An 
o_bjective wets to determine= the ¢'0n~_nlration.r~pert~ Cu~ ~t ~plitiiP~tida 
~,  pli~00 for ex viva platolet el00r0gatton (PA) ~ plata~t GPllb-411a 
receptor occupancy (RO) The extent RO w_as dotermi~ I~y the. I~ndin 0
of the_ I~ m,~ wHIch meaiiures the I;~rfant of total GPllb-~tIlel re~pptors 
With Pound drug, Both PA en~ RO were famed out I;~om e~tifil0ati(3~ w~ 
administered, m timepomt~ after dm 0 initiation, plier to drug disr, Onl~nL~tion, 
and at 4 hr and 8 hr after di=¢,onfinuation, 
Re, u/is: More than 80% et palmate achmved 80% inhtl~tion of PA to 20 
~M ADP immod~taly after the IV ~mlus ~ under staa~/$5tlto conditian~, 
Platelet inh;bitmn was rap~dty reverses with PA returning to I~lselifle within 
4-8 hr after discontinuation o! infusion, The RO results temporaJly parai!eled 
the profile ol inhibition of PA. 45% of the patients ~hieved 80% RO after 
the IV bolus and more than 65% ach i~ ~ Re under Ste,L~y state 
conditions. A Re ol less than 60% was measured at 8 hr after discontinuation 
of infuszon. Furthermore, PK data proved a strong relationship between 
epbrubat~le plasma Car, contralto,s and Re. 
Conc/uszons: Eptif-d~liele caused a concentration dependent effect on Re 
that mirrored tt~ olosen~cl inhibition of PA. Re has advantages in that 8 
pre~lrug sample is net mquirecl and assessment can be corned Out up to 72 
hm post blo~cl collection. Re is an excellent altemat~e method far r~onlt0nng 
receptor blockade. 
[ 1028.1101 Dose Ranging Study of Intravenous RPR 109891 
.... in Patients Wdh Acute Coronary Syndromes - 
Results of  TIM115A 
R.P. Giugliano, C.H. McCabe, fl.F. Sequeira, TO. Henry, R.N. Pians, 
MJ. Schweiger, H.S. Mustier, S. Borzak, M.D. l"ischlor, J.-F. Tamby, 
K.E. Ramsay, MV, Jacaski, R.J, Wise, E. Braunwald. Brigham and 
Women's Hospital, Boston, MA, USA 
Platelet glycOpmteth Ilbillla receptor blockade is beneficial in bigh-nsk un- 
stable angina and angiop;asty. RPR 109891 is a unique competitive inhibitor 
because it is available in both IV and oral formulations, To stucly the dose 
response of the IV formulation, TIM115A is randomizing patients with acute 
coronary swdmmes to receive IV RPR 109891 for 24-96 hours. The primary 
endpolnt is inhibition of ptatelot aggregation 0PA) using ADP-20 pM Mean 
IPA at 20 minutes, pro-stop and 2-4 hfs post stop am shown below for 5 
ton" 60/0.8 (n=t3) 
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regimens, NO major and one significant minor bleed have been observed in 
hospital in 62 patlonto. 
Conclusions: IV RPR 109891 aohleved plotolet inhibition with a cl~ar 
close,response and deoervos further study as part of a continuous IV followed 
by 0ral strategy for treatment of acute coronary syndromes, 
~ SulltalnSd Plstelet OP lib/Ills Blookeds With Oral 
Orboflbnn: Interim 8arMy end Tolersblllty 
Rolultl of the SOAR Study 
P,C, Oeadw(knie, J,J, Ferguson, O,J, Karalakas, D, Fit=gerald, R,J, Andare, 
O,M, Bum0, 0,8, Bryx~nnkt, VA M~lcal Center/University of California San 
Fran¢l#¢'o $¢hool of M~l¢lna, Frt~no, CA; G, D, Saarlo ~ Co, SkOklO, IL, 
USA 
~/,ground: SOAR ~tlfaty of ~Kooflban in ~cute Coronary _~esoeroh) is ¢1 
ran~iomized, plocebo.c0ntrollod study comparing four dosage levels of the 
oral platelet OP lib/Ills Inhibitor Orboflban to placebo In p~tlonts hospitalized 
with unstable angina (~,(~ houm but E120 hour~) or myocardial Infamtlon, 
P~tiants (n ~ 259) worn randomized to receive O~ofiben (~0, 40, 50 mo BlO 
or 60 mg QD) or pl~oebo for up to 3 months, All patients ~elvad conoomitant 
asptnn (162 mo/~ay), 
M~fhoo~: Patlento wsr~ aase8t~od for ~dvor~e ovont~ (AE) ~nd bloedlng 
events (BE) during Initlal hospltall,atlon and at follow up visits, 
Ro#glt~: At the time of this Inform an~lysis, there wero a total o! 1:]0 
patients completing a minimum of 1 month tro~tmant, The withdrawal rates 
w~m a8 follows: 
P ~10 10 40 010 50 0tO f~0 qO 
BE withdrawal (%) 0 1 (1%) = (4%) O ~ (4%) 
AlE withdr~wtt (%) 4 (9%~) 9 (10%) e (11%) 6..(le%) 6 (1~%) 
Ble(~ling ovents by treatment ware as follow~; 
P 30 810 40 8i0 50 010 50 QD 
Instgnl~nl 4 ? 7 10 4 
MII¢I t ~ 6 4 7 
8ev~r~ O I 0 O 0 
TOlill (%) 5 (12) 10 (20) 13 (28) 14 (31) 11 (24) 
Conclusion: Ofooflbsn produced dose-related increases in insignificant 
and mild bleeding events but was well tolerated uring ~hronic therapy. 
• Primary Reperfuslon in Acute Myocardial 
Infamtlon With RooPro and Heparln: Interim 
Results of ReoMI Pilot Study 
R. Makkar, N. Elgiar, ~, Gaff, E. F~/, L. ~arr, C. O'Haem, 1". Fisch011, 
F, Lltvack, Cedat~.Sin~ti Medical Center, Los Angeles, CA, USA 
R~oMI (RaoPre In MiD is a multlcenter pilot study to assess the efficacy 
of ReoPro In attaining primary ropertuslon in acute myOcardial Infamtlon. 
Patients w~th acute Q, wava MI, pmsenUng within 6 hours of chest pain are 
treated with aspirin (325 mg po), heparln (70 u/k9 iv) and ReoPro bolus (0.25 
rng/kg iv) followed by continuous infusion (0,10 mg/~g) in the emergency 
room. All patients undergo acute coronary anglography and intervention if 
clinically indicated, Primary end point is ability to attain TIMI grade It or III 
flow at anglogrsphy. Secondary endbeints include acute procedural success 
rate, in-hospital death, relnfar¢tlon, emergency re-intervention and bleeding 
c~mplicatiens. At the time el submission 20 patients (mean age 57 y, 17 
males) from 6 centers have been enrolled in the study, Average time between 
administration ofReoPro and baseline angiogram was 42 minutes. 
TIMI flows at baseline angiogaphy wore as follows: 
TIMI O: 8/20, TIMI t: 7120, TIMI Ih 2/20, TIMI II1:3/20 
Time between ReoprO and angiogram: 
<30 minutes: TIMI It or III flow in 0~11 patients 
->30 minutes: TIMI II Or III flow in 519 patients 
Corenaw intervention was successfully pedormed in 19 patients. Com- 
posite secondary endpoints of death (1), recurrent MI (0), emergent revas- 
cularization (1) and significant bteedin9 complications (2) occurred in 3/20 
patients. One month follOwup data will be presented. 
Conclusion: In~,3rim analysis suggest; that F,eoMI strategy ields TIMI Will 
flow in less than 50% patients, though repertusion may be time dependent. 
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~ Effloscy of Strategy for Menngsmlnt Invoslve the 
of the Isost.lnfamtlon Gero'loganlg IBho~k 
H, P~iroz.Coatolisno, J,A, Oorrono, J, Eli~O9a, E,J, O~r¢(o, 
J,L, LOpez,SendOn, J L, Oalodn, "Orc~orto MataP~n" General klOi~tal, 
Ma~lrld, Spain 
B~ckgmun#: Primary angloplasty 6~ma to improve the progn~t8 of Ix~t, 
infarction ¢afdlogonlo Shock (Ca), Our aim was to evaluate whether inva~ 
m~nagament of saute myoca~ial infarction (AMID ¢ompli~t~l with CS r~ 
duces the in*hoepitt~l mo~lolity, 
Matinee: From 1651 I~ttont~ with AMI admitted to o~r Corof~ly C~,  
Unit from J~nu~ry 19~4 to April t~19T, t~l  I~tionta (0~4%) d0Vol¢~ C~ 
unrelated to mechanical ¢0mpllc~ti~ns, The MratoOy of manp0omont w~ 
¢onslde~d tnvaoivo if a ¢OrOna~ angiography Ontanding to r~ve~ulan~.eD 
w~s In,looted in the fi~t 24 hours alter the coronary e,,~nt ovoIvi~l in C$, 
I~very other strategy, including throt~l~ly$ie, woo considered ¢olls~/atiw, 
Fo~.thr~ ~tient8 who developed CS tn~idiously w~re exolud~l, bocau'~) 
e definite vent which ¢ou!d (~t~ to e cattain aOfUAtiO~ at a partiojIM moment 
gould not b~ Indonti!i~, 
R~sgI~: Nlnety.alx p~tiente we~ i~lude(J, The atlategy was invssive in 
6t patients (64%D and ¢onsewativ~ in 31 (~,%); four i~tlent~ (4%D were 
unolassift~;J k~ocaosa they died ~ihortly after their admission, The in-hosl~n! 
mortality Of the invasive strategy wee lower than the consorv~zSve (70 vs. 90%; 
OR 0,3 [0.1-,0.6]; p < 0,05). However, alter adjusting by other pred¢tora 
of mortality, such as age and prior ischemio heart disease, the strategy 
of management was not en tndel~ndent predictor of in-hospltal me.Sty 
(Table), 
In,,~o~tat,m~, alay OR C195% P 
Age (OR per 5 year increase) 155 1.15--2.10 0003 
Prior tschemi¢ h~rt diso~zo 3.30 1 O7-11.11 0.04 
I nWSW~ strategy 0.81 O. 15"..3.65 0.78 
Conclusions: The lower mortality o! patients managed invasively might 
be due to betng younger, having less prior ischemic disease or other factors 
rather than the efficacy inherent o the treatment. The role of invasive strategy 
of post.infarrion CS needs further evaluation. 
j i029:i sO [ o.e Year su,~lv= Amo.g ~tio.to With 
Myocarcllal Infarction Complicated by 
Cardlogenlc Shock Alive at 30 Says, and the 
Impact of Early Revascuierization: Results From 
GUSTO-1 
P.B. Berger, R. Tuttis, D.R, Holmes, Jr.. The GUSTO.I Investigators. Mayo 
Clinic, Rochester MN, USA 
Thirty-day Survival is increased in p~tlents (pts) with myOcardial infarction (MI) 
complicated by cardiogenic shock who undergo eady revascularizaben, even 
after adjusting for differences in baseline characteristics and other sources of 
bias. However. longer term survival rates and the duration of benefit of eady 
revascularization are unknown, We analyzed 30-day survivors in GUSTO-t 
and identified 1321 pts who had had shock (Group 1) and 36,333 who did not 
(Group 2). Group 1 pts were older and sicker in many ways. At 1 yr, 88.0% 
Of Group 1 were alive vs 97.4% of Group 2 (p = 0.0001). Among Group 1 
pts, 44% had undergone revascularizarion within 30 days (Group 1A), and 
56% had not (Group 1B). At 1 yr, 91.7% of Group 1A pts were alive vs 85.3% 
Of Group 18 (p = 0,0001), Multivariate logistic regression analysis of Group 
1 pts revealed that revascularization within 30 days of MI was an important 
independent predictor of survival to 1 yr (odds ratio 0.41 [0.25, 0.67], p = 
0.0001). 
Conclusions: Among pt.~ with MI complicated by shock, most who sur- 
vive 30 days (L3%) are alive at 1 year. Eady revascularization isassociated 
with improved survival in shock pts for at least 1 year, even among 30-day 
survivors. The high survival rate and persistent benefits of eady revascular- 
ization Support an oath, aggressive revascularization strategy among such 
pts. 
